These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21525868)

  • 21. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
    Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
    JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.
    Hsu CY; Chiu WC; Chen JF; Chou CL; Su YJ; Yu SF; Cheng TT
    J Bone Miner Metab; 2015 Sep; 33(5):577-83. PubMed ID: 25240801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces.
    Crilly RG; Kloseck M; Chesworth B; Mequanint S; Sadowski E; Gilliland J
    Osteoporos Int; 2014 Jan; 25(1):205-10. PubMed ID: 23907572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
    Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
    Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing and evaluating FRAX
    Chan DC; McCloskey EV; Chang CB; Lin KP; Lim LC; Tsai KS; Yang RS
    J Formos Med Assoc; 2017 Mar; 116(3):161-168. PubMed ID: 27117886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
    Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
    Moriwaki K; Mouri M; Hagino H
    Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
    Wang Z; Ward MM; Chan L; Bhattacharyya T
    Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
    Lin TC; Yang CY; Kao Yang YH; Lin SJ
    Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
    Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
    J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.